newsfilter
← Earnings
Earnings Releases·

SELLAS Life Sciences — Third Quarter 2026 Earnings Summary

SELLAS Life Sciences reported a net loss of $10.1 million for the third quarter of 2026, with research and development expenses rising to $7.0 million due to costs associated with the Phase 3 REGAL trial and potential Biologics License Application for GPS. The company holds $134.7 million in cash and cash equivalents as of September 30, 2026, providing capital to advance its clinical programs. Topline primary endpoint results for the Phase 3 REGAL trial of Galinpepimut-S in acute myeloid leukemia are expected to be announced following the 80th event milestone. Additionally, 40 patients have been enrolled in the Phase 2 trial of tambiciclib (SLS009) for newly diagnosed AML, with preliminary data anticipated in the fourth quarter.

Company
SELLAS LIFE SCIENCES GROUP INC
Sector
Healthcare
Industry
Biotechnology